Table 4-.
Univariate results for association of studied factors with risk of lymphedema.
| Variable | Hazard Ratio | 95% CI | P value |
|---|---|---|---|
| Clinical Characteristics | |||
| Age at diagnosis | 1.00 | 0.98–1.03 | 0.76 |
| BMI | 1.09 | 1.04–1.15 | 0.0007 |
| Pathologic Characteristics | |||
| Invasive Tumor Size | 1.04 | 0.89–1.22 | 0.64 |
| Breast Surgery | |||
| Mastectomy vs. Lumpectomy | 1.39 | 0.74–2.60 | 0.31 |
| Axillary Surgery | |||
| ALND vs. SLNB | 7.08 | 0.98–51.40 | 0.05 |
| # LNs removed | 1.03 | 0.99–1.07 | 0.11 |
| # Positive LNs | 1.02 | 0.98–1.06 | 0.39 |
| Radiation Therapy | |||
| SC vs. SC + PAB | 1.15 | 0.61–2.16 | 0.66 |
| Regular vs. Wide Tangents | 0.71 | 0.10–5.17 | 0.74 |
| Chest wall vs. Intact en face boost | 1.24 | 0.66–2.30 | 0.50 |
| 6 MV vs. 10 MV SC field beam energy | 1.27 | 0.56–2.87 | 0.57 |
| 5000 cGy vs. 5040 cGy SC field total dose | 1.52 | 0.81–2.86 | 0.19 |
| 180 cGy vs. 200 cGy SC field fraction size | 0.77 | 0.42–1.42 | 0.40 |
| SC field: <1/3 vs. >2/3 of humeral head | 0.87 | 0.38–1.99 | 0.73 |
| SC field: 1/3–2/3 vs. >2/3 humeral head | 0.67 | 0.26–1.74 | 0.41 |
| Systemic Therapy | |||
| Neoadjuvant Chemotherapy | 1.04 | 0.54–1.99 | 0.92 |
| Adjuvant Chemotherapy | 0.70 | 0.33–1.46 | 0.34 |
| Hormone Therapy | 1.35 | 0.60–3.03 | 0.47 |
Abbreviations: BMI= Body Mass Index, SLNB = Sentinel lymph node biopsy, ALND = Axillary lymph node dissection, LN = Lymph node, SC = supraclavicular, PAB = posterior axillary boost